Breaking News Instant updates and real-time market news.

LLY

Eli Lilly

$111.91

-1.4 (-1.24%)

, INCY

Incyte

$66.09

1.66 (2.58%)

18:44
10/21/18
10/21
18:44
10/21/18
18:44

Eli Lilly, Incyte shares updated safety analysis of Olumiant in active RA

Eli Lilly (LLY) and Incyte (INCY) announced findings from an updated integrated safety analysis of Olumiant based on an ongoing long-term extension study of rheumatoid arthritis patients treated up to six years. The analysis provides further support for the characterization of Olumiant's safety profile, and was shared as an oral presentation at the American College of Rheumatology/Association of Rheumatology Health Professionals Annual Meeting in Chicago, Illinois. Olumiant is indicated in the U.S. for the treatment of adults with moderately-to-severely active RA who have had an inadequate response to one or more tumor necrosis factor antagonist therapies. This long-term safety evaluation of Olumiant included all patients with active RA exposed to the medicine during eight randomized trials and one LTE study. Dose responses were evaluated based on the four Phase 2/3 trials in which patients were randomized to receive the 2-mg or 4-mg dose of baricitinib, including data from the LTE. Incidence rates were calculated per 100 patient-years. In total, 3,492 patients received Olumiant for 7,860 patient-years of exposure. More than three-quarters of these patients were treated for at least one year, and half were treated for at least two and a half years. Overall, adverse event IRs per 100 PYE were consistent with prior analyses, and did not show evidence of increase with longer-term treatment. The malignancy IR was 0.8. The major adverse cardiovascular event IR was 0.5. The serious infection IR was 3.0. The IR for venous thromboembolism, which combined events of deep venous thrombosis and pulmonary embolism, was 0.5. Fewer than 1.0% of patients discontinued treatment with Olumiant due to abnormal lab results. The permanent discontinuation IR due to AEs was 5.4.

LLY

Eli Lilly

$111.91

-1.4 (-1.24%)

INCY

Incyte

$66.09

1.66 (2.58%)

  • 22

    Oct

  • 30

    Oct

  • 06

    Nov

  • 07

    Nov

LLY Eli Lilly
$111.91

-1.4 (-1.24%)

10/16/18
WELS
10/16/18
NO CHANGE
WELS
Drug price in ads not impactful, may cause confusion, says Wells Fargo
Wells Fargo analyst David Maris acknowledges that the U.S. Department of Health and Human Services' proposal to include drug prices in advertisements has a "noble goal" of making drugs more affordable and keeping patients well informed. However, given how different list prices are relative to out of pocket costs, "one must ask if this is increasing transparency or likely going to lead to more confusion," he contends. The analyst also believes that the unintended consequence could be worse care, while noting that the drug price information will likely fall into the category of the side effect information in drug ads currently, tuned out by many and will have no material impact. While he supports the idea of increased transparency, Maris wonders whether the potential benefit is not outweighed by the potential negative for the most vulnerable. Publicly traded companies in the space include AstraZeneca (AZN), Bristol-Myers (BMY), Eli Lilly (LLY), GlaxoSmithKline (GSK), Johnson & Johnson (JNJ), Merck (MRK), Novartis (NVS), Pfizer (PFE), Roche (RHHBY) and Sanofi (SNY).
10/15/18
FBCO
10/15/18
INITIATION
Target $36
FBCO
Neutral
Elanco initiated with a Neutral at Credit Suisse
Credit Suisse analyst Erin Wright started Elanco (ELAN) with a Neutral rating and $36 price target. As the fourth-largest animal health therapeutics company, Elanco is highly levered to robust industry fundamentals across livestock and companion animal markets, and earnings growth should accelerate on dedicated innovation efforts and dramatically improving cost structure as a more nimble unencumbered entity, unchained to Eli Lilly (LLY), its large pharmaceutical parent, she contends.
10/12/18
CHLM
10/12/18
INITIATION
Target $33
CHLM
Hold
Elanco initiated with a Hold at Craig-Hallum
Craig-Hallum analyst Kevin Ellich initiated Elanco Animal Health (ELAN) with a Hold rating and $33 price target. While Elanco is well positioned to expand gross margin by about 10 percentage points over the next five years which will drive mid-teens operating income growth and Ellich likes the company's focus on pet therapeutics and disease prevention as well as food animal future protein and health, he believes shares are fairly valued trading at ~19x FY20 EV/EBITDA, which is an 8% premium to industry leader Zoetis (ZTS). With shares up 35% from the September 19 IPO price of $24, the analyst tells investors in a research note that he looks to get more positive on pullbacks, improved liquidity as Eli Lilly (LLY) still owns 80% of Elanco stock, and improved visibility on longer-term growth drivers that could lead to upside to his projections.
10/08/18
GUGG
10/08/18
INITIATION
Target $132
GUGG
Buy
Eli Lilly initiated with a Buy at Guggenheim
Guggenheim analyst Seamus Fernandez started Eli Lilly with a Buy rating and $132 price target, calling out the company's "Impressive execution as the industry's leading fast-follower." He sees limited downside from current levels with the potential for revaluation around the Phase 3 study readout for tanezumab.
INCY Incyte
$66.09

1.66 (2.58%)

10/01/18
CANT
10/01/18
INITIATION
Target $73
CANT
Neutral
Incyte initiated with a Neutral at Cantor Fitzgerald
Cantor Fitzgerald analyst Alethia Young started Incyte with a Neutral rating and $73 price target.
09/24/18
LEER
09/24/18
INITIATION
Target $78
LEER
Market Perform
Incyte initiated with a Market Perform at Leerink
Leerink analyst Andrew Berens started Incyte with a Market Perform rating and $78 price target.
09/17/18
GUGG
09/17/18
INITIATION
Target $72
GUGG
Neutral
Incyte initiated with a Neutral at Guggenheim
Target $72.
09/13/18
JANY
09/13/18
INITIATION
Target $17
JANY
Neutral
Janney Montgomery Scott starts Concert Pharmaceuticals at Neutral
As previously reported, Janney Montgomery Scott initiated Concert Pharmaceuticals (CNCE) with a Neutral rating, with analyst Esther Hong setting a $17 fair value estimate on the shares. She believes AVP-786, which is in Phase 3 in Alzheimer's agitation, has blockbuster potential and she is positive on its lead program, CTP-543 for the treatment of Alopecia Areata. However, Hong remains on the sidelines pending the final decision on CTP-543's patent after Incyte filed an Inter Partes Review petition, noting that the PTAB granted a rehearing request, which it rarely does. She sees the IPR ruling as difficult to predict at this stage.

TODAY'S FREE FLY STORIES

HYMTF

Hyundai Motor

$0.00

(0.00%)

21:09
03/21/19
03/21
21:09
03/21/19
21:09
Periodicals
Breaking Periodicals news story on Hyundai Motor »

Elliott Management loses…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SMTS

Sierra Metals

$1.64

0.05 (3.14%)

21:01
03/21/19
03/21
21:01
03/21/19
21:01
Hot Stocks
Sierra Metals announces 66% of Yauricocha Mine workers waged illegal strike »

Sierra Metals announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Mar

LGF.B

Lionsgate

$15.17

0.4 (2.71%)

, NFLX

Netflix

$378.09

2.94 (0.78%)

20:32
03/21/19
03/21
20:32
03/21/19
20:32
Recommendations
Lionsgate, Netflix, Apple, Spotify, Roku analyst commentary at SunTrust »

Apple event may be…

LGF.B

Lionsgate

$15.17

0.4 (2.71%)

NFLX

Netflix

$378.09

2.94 (0.78%)

AAPL

Apple

$195.07

6.93 (3.68%)

SPOT

Spotify

$144.04

-0.01 (-0.01%)

ROKU

Roku

$66.82

1.86 (2.86%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Mar

TSLA

Tesla

$274.10

0.6 (0.22%)

20:13
03/21/19
03/21
20:13
03/21/19
20:13
Hot Stocks
End of Tesla's referral program reduced costs, allowed to pass on savings »

In its blog, Tesla…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HSBC

HSBC

$41.07

-0.16 (-0.39%)

, BLK

BlackRock

$430.32

0.35 (0.08%)

19:44
03/21/19
03/21
19:44
03/21/19
19:44
Periodicals
Breaking Periodicals news story on HSBC, BlackRock »

HSBC reaches deal to use…

HSBC

HSBC

$41.07

-0.16 (-0.39%)

BLK

BlackRock

$430.32

0.35 (0.08%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Oct

UBER

Uber

$0.00

(0.00%)

, ICE

IntercontinentalExchange

$73.36

0.15 (0.20%)

19:21
03/21/19
03/21
19:21
03/21/19
19:21
Periodicals
Uber selects NYSE for 2019 IPO, Bloomberg reports »

Uber (UBER) has picked…

UBER

Uber

$0.00

(0.00%)

ICE

IntercontinentalExchange

$73.36

0.15 (0.20%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    May

  • 17

    May

  • 28

    May

PIN

Pinterest

$25.63

-0.07 (-0.27%)

19:18
03/21/19
03/21
19:18
03/21/19
19:18
Periodicals
Pinterest moves up IPO timing, seeks to list shares on NYSE in April, WSJ says »

Pinterest has moved up…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TAP

Molson Coors

$60.80

1.04 (1.74%)

, BUD

AB InBev

$83.94

0.52 (0.62%)

18:57
03/21/19
03/21
18:57
03/21/19
18:57
Periodicals
MillerCoors sues AB InBev over corn syrup claims, WSJ reports »

MillerCoors, a subsidiary…

TAP

Molson Coors

$60.80

1.04 (1.74%)

BUD

AB InBev

$83.94

0.52 (0.62%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    May

OSS

One Stop Systems

$2.52

(0.00%)

, AMRN

Amarin

$18.77

-0.24 (-1.26%)

18:40
03/21/19
03/21
18:40
03/21/19
18:40
Hot Stocks
Fly Intel: After Hours Movers »

UP AFTER EARNINGS: One…

OSS

One Stop Systems

$2.52

(0.00%)

AMRN

Amarin

$18.77

-0.24 (-1.26%)

GME

GameStop

$10.54

0.06 (0.57%)

DLNG

Dynagas LNG

$2.61

0.025 (0.97%)

ZUO

Zuora

$24.34

0.62 (2.61%)

CAL

Caleres

$25.75

-0.08 (-0.31%)

OPNT

Opiant Pharmaceuticals

$14.00

0.5 (3.70%)

NKE

Nike

$88.05

1.3597 (1.57%)

CTAS

Cintas

$208.00

2.78 (1.35%)

CNAT

Conatus

$2.91

0.02 (0.69%)

GG

Goldcorp

$11.17

0.13 (1.18%)

NEM

Newmont Mining

$34.32

0.44 (1.30%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Mar

  • 21

    Mar

  • 21

    Mar

  • 21

    Mar

  • 21

    Mar

  • 21

    Mar

  • 22

    Mar

  • 25

    Mar

  • 02

    Apr

  • 04

    Apr

  • 04

    Apr

  • 11

    Apr

  • 16

    Apr

  • 23

    Apr

UBER

Uber

$0.00

(0.00%)

, ICE

IntercontinentalExchange

$73.36

0.15 (0.20%)

18:40
03/21/19
03/21
18:40
03/21/19
18:40
Periodicals
Uber selects NYSE for 2019 IPO, Bloomberg reports »

Uber (UBER) has picked…

UBER

Uber

$0.00

(0.00%)

ICE

IntercontinentalExchange

$73.36

0.15 (0.20%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    May

  • 17

    May

  • 28

    May

CVS

CVS Health

$57.40

1.23 (2.19%)

18:34
03/21/19
03/21
18:34
03/21/19
18:34
Hot Stocks
CVS Health CEO: Off to great start with Aetna integration »

In an interview on…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Mar

SPX

S&P 500

$0.00

(0.00%)

, SPY

SPDR S&P 500 ETF Trust

$284.63

3.19 (1.13%)

18:30
03/21/19
03/21
18:30
03/21/19
18:30
Periodicals
EU to offer U.K. Brexit negotiating period extension, Reuters says »

The EU plans to grant the…

SPX

S&P 500

$0.00

(0.00%)

SPY

SPDR S&P 500 ETF Trust

$284.63

3.19 (1.13%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NOK

Nokia

$6.26

-0.03 (-0.48%)

18:20
03/21/19
03/21
18:20
03/21/19
18:20
Periodicals
Nokia not planning to take on new business in Iran in 2019, Reuters says »

Nokia said it does not…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    May

DNR

Denbury Resources

$1.95

0.06 (3.17%)

, PVAC

Penn Virginia

$54.29

1.74 (3.31%)

18:17
03/21/19
03/21
18:17
03/21/19
18:17
Hot Stocks
Denbury Resources: Penn Virginia deal was unlikely to receive majority approval »

Chris Kendall,…

DNR

Denbury Resources

$1.95

0.06 (3.17%)

PVAC

Penn Virginia

$54.29

1.74 (3.31%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    May

IMMP

Immutep

$2.40

-0.095 (-3.82%)

18:11
03/21/19
03/21
18:11
03/21/19
18:11
Hot Stocks
Immutep announces U.S. patent for Eftilagimod Alpha in cancer »

Immutep Limited is…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PVAC

Penn Virginia

$54.29

1.74 (3.31%)

, DNR

Denbury Resources

$1.95

0.06 (3.17%)

18:08
03/21/19
03/21
18:08
03/21/19
18:08
Hot Stocks
Penn Virginia, Denbury Resources mutually agree to terminate merger pact »

Penn Virginia (PVAC)…

PVAC

Penn Virginia

$54.29

1.74 (3.31%)

DNR

Denbury Resources

$1.95

0.06 (3.17%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    May

LLL

L3 Technologies

$208.75

1.535 (0.74%)

17:44
03/21/19
03/21
17:44
03/21/19
17:44
Hot Stocks
L3 Technologies awarded $131.78M Air Force contract »

L3 Technologies has been…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    Apr

  • 01

    May

GM

General Motors

$37.35

0.35 (0.95%)

17:42
03/21/19
03/21
17:42
03/21/19
17:42
Periodicals
GM to invest $300M in Orion EV/AV factory, Reuters reports »

General Motors intends to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Mar

  • 30

    Apr

GD

General Dynamics

$169.81

1.21 (0.72%)

17:42
03/21/19
03/21
17:42
03/21/19
17:42
Hot Stocks
General Dynamics awarded $465.15M Navy contract for CVN shipyard availabilities »

General Dynamics has been…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    May

NKE

Nike

$88.05

1.3597 (1.57%)

17:41
03/21/19
03/21
17:41
03/21/19
17:41
Earnings
Breaking Earnings news story on Nike »

Nike sees FY20 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Mar

  • 04

    Apr

  • 04

    Apr

NKE

Nike

$88.05

1.3597 (1.57%)

17:39
03/21/19
03/21
17:39
03/21/19
17:39
Earnings
Nike sees Q4 revenue growth in high single-digit range, consensus $10.38B »

Sees Q4 gross margin…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Mar

  • 04

    Apr

  • 04

    Apr

NKE

Nike

$88.05

1.3597 (1.57%)

17:36
03/21/19
03/21
17:36
03/21/19
17:36
Hot Stocks
Nike says it is not taking China momentum for granted »

Says leveraging the power…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Mar

  • 04

    Apr

  • 04

    Apr

LOV

Spark Networks

$11.29

(0.00%)

17:34
03/21/19
03/21
17:34
03/21/19
17:34
Hot Stocks
Spark Networks to acquire Zoosk, sees adjusted EBITDA to exceed $50M in 2020 »

Spark Networks announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ACA

Arcosa

$29.74

-0.16 (-0.54%)

17:29
03/21/19
03/21
17:29
03/21/19
17:29
Initiation
Arcosa initiated at DA Davidson »

Arcosa initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

JNJ

Johnson & Johnson

$138.09

0.86 (0.63%)

17:24
03/21/19
03/21
17:24
03/21/19
17:24
Hot Stocks
Johnson & Johnson sees Q1 charge of about $700M related to AL-8176 »

On March 21, Johnson…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Apr

  • 25

    Apr

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.